-

Ultivue to Participate in the Stifel 2021 Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, will participate in the Stifel 2021 Virtual Healthcare Conference to be held November 15th – 17, 2021. The conference incorporates presentations and innovative panel discussions hosted by senior leadership in the health care industry.

Ultivue’s President and Chief Executive Officer, Jacques Corriveau, and Chief Financial Offer, Richard C. Malabre, will present at 9:20 am ET on November 17. Interested parties may listen to the presentation using the following link: Ultivue Stifel Presentation

“We look forward to meeting investors and sharing our vision for continued rapid growth and exciting new products. Ultivue is at the forefront of innovation for tissue-based assays providing critical insights to researchers and pathologists from precious samples” said Jacques Corriveau, President and CEO.

About Ultivue

Ultivue provides researchers in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.

About Stifel

Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. The Company’s broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities.

Stifel hosts several client conferences and events each year, attracting top institutional investors as well as leading companies in their sectors of focus.

Contacts

Richard C. Malabre
Chief Financial Officer
+1 617.710.1341
Richard.Malabre@Ultivue.com

Adrian Arechiga Ph.D.
VP Marketing
+49 176 3039 0757
Adrian.Arechiga@Ultivue.com

Industry:

Ultivue

Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)

Contacts

Richard C. Malabre
Chief Financial Officer
+1 617.710.1341
Richard.Malabre@Ultivue.com

Adrian Arechiga Ph.D.
VP Marketing
+49 176 3039 0757
Adrian.Arechiga@Ultivue.com

More News From Ultivue

Ultivue and ngTMA® Announce Collaborative Agreement to Provide Multiplex and Spatial Analysis for Clinical Research

CAMBRIDGE, Mass. & BERN, Switzerland--(BUSINESS WIRE)--Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies and, the Translational Research Unit (TRU) platform of University of Bern, that develops novel workflows for tissue microarray (ngTMA®) construction, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and the use of next generation TMAs to unlock spatial analysis in scientific research...

Ultivue Announces AI Partner Ecosystem to Accelerate Analysis of Multiplex Immunofluorescence Image Data in Translational Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, Inc., an industry leader in multiplexing assays and analytics solutions for tissue biomarker studies, announced today multiple collaborations for AI-powered spatial phenomics solutions for translational research groups and Biopharma. Ultivue develops unique workflows for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically...

Ultivue Announces Co-Marketing and Co-Development Collaboration with Paige for AI-Powered Biomarker Imaging Solutions for Precision Medicine

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, and Paige, the global leader in AI-based diagnostic software in pathology, today announced a partnership to collaborate on the co-development and co-marketing of AI-powered spatial immunophenotype capabilities to pharmaceutical and research customers. Collaborative efforts will initially focus on the development of AI to enable improved understanding of the tumor microe...
Back to Newsroom